# Medicare Benefits Schedule

# **Summary of Changes**

Effective 1 March 2009

© Commonwealth of Australia 2009

Online ISBN: 1-74186-735-5 Print Copyright

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney-General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <a href="http://www.ag.gov.au/cca">http://www.ag.gov.au/cca</a>

#### **Online Copyright**

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney-General's Department, Robert Garran Offices, National Circuit, Canberra ACT 2600 or posted at <a href="http://www.ag.gov.au/cca">http://www.ag.gov.au/cca</a>

#### **Publications Approval Number: P3-4526**

## Summary of Additions, Deletions, and Revisions undertaken since 1 November 2008

New Items are indicated as "New". Deleted items are indicated as "Del".

Amended items are indicated as "Amend" Within revised items, the deleted language appears with a double strikethrough while new text appears <u>underlined</u>. These changes will be highlighted in yellow.

**Note:** Revisions to the headings, notes, introductory paragraphs, and cross references are not included in this summary of changes.

#### New Items (New)

**1 March 2009** <u>11823</u> <u>32220</u> <u>32221</u>

**1 February 2009** <u>63464</u> <u>63467</u>

Deleted Items (Del)

No deleted items.

#### Amended Description (Amend)

1 December 2008615416154461553615566156561568

**1 January 2009** <u>10992</u>

**1 February 2009** 61462 61484 61485

## CHANGES TO ALLIED HEALTH SERVICES - effective 1 January 2009

From 1 January 2009, the requirement to claim a rebate for chronic disease management care planning items before items 10950 - 10970 and 81100 - 81125 can be claimed will be removed. However, note that eligibility requirements for these items have not changed.

#### **Table of Contents**

SUMMARY OF ADDITIONS, DELETIONS, AND REVISIONS UNDERTAKEN SINCE 1 NOVEMBER 2008	
New Items (New) 1 March 2009 1 February 2009 Deleted Items (Del) Amended Description (Amend) 1 December 2008 1 January 2009 1 February 2009 CHANGES TO ALLIED HEALTH SERVICES - EFFECTIVE 1 JANUARY 2009	3 3 3 3 3 3 3 3 3 3 3 3 3 3
CATEGORY 2 – DIAGNOSTIC PROCEDURES	5
GROUP D1 - MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS SUBGROUP 7 - GASTROENTEROLOGY & COLORECTAL 11823	5
CATEGORY 3 – THERAPEUTIC PROCEDURES	6
GROUP T8 - SURGICAL OPERATIONS SUBGROUP 2 - COLORECTAL 32220 32221	6 6
CATEGORY 5 – DIAGNOSTIC IMAGING SERVICES	7
GROUP I4 - NUCLEAR MEDICINE IMAGING	7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 9 9 9 9
CATEGORY 8 – MISCELLANEOUS SERVICES	10
GROUP M1 - MANAGEMENT OF BULK-BILLED SERVICES 10992	

### **Category 2 – Diagnostic Procedures**

#### GROUP D1 - MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS

#### **SUBGROUP 7 - GASTROENTEROLOGY & COLORECTAL**

CAPSULE ENDOSCOPY to conduct small bowel surveillance of a patient diagnosed with Peutz-Jeghers syndrome, using a capsule endoscopy device approved by the Therapeutic Goods Administration. The procedure includes the administration of the capsule, imaging, image reading and interpretation, and all attendances for providing the service on the day the capsule is administered (not being a service associated with double balloon enteroscopy).

 Medicare benefits are only payable for this item if: the service has been performed by a specialist or consultant physician with endoscopic training that is recognised by the Conjoint Committee for the Recognition of Training in Gastrointestinal Endoscopy; and the patient to whom the service is provided has been conclusively diagnosed with Peutz-Jeghers syndrome (PJS)
 11823
 New This item is available once in any two year period. (See para D1.23 of explanatory notes to this Category)
 2009
 Fee: \$1,883.90 Benefit: 75% = \$1,412.95 85% = \$1,815.80

## **Category 3 – Therapeutic Procedures**

	<b>GROUP T8 - SURGICAL OPERATIONS</b>			
	SUBGROUP 2 - COLORECTAL			
<b>32220</b> New 1 Mar 2009	Insertion of an artificial bowel sphincter for severe faecal incontinence in the treatment of a patient for whom conservative and other less invasive forms of treatment are contraindicated or have failed (Anaes.) (Assist.) (See para T8.32 of explanatory notes to this Category) Fee: \$835.05 Benefit: 75% = \$626.30 85% = \$766.95			
<b>32221</b> New 1 Mar 2009	Removal or revision of an artificial bowel sphincter (with or without replacement) for severe faecal incontinence in the treatment of a patient for whom conservative and other less invasive forms of treatment are contraindicated or have failed (Anaes.) (Assist.) (See para T8.32 of explanatory notes to this Category) <b>Fee:</b> \$835.05 <b>Benefit:</b> 75% = \$626.30 85% = \$766.95			

٦

# Category 5 – Diagnostic Imaging Services

	GROUP I4 - NUCLEAR MEDICINE IMAGING		
<b>61462</b> Amend 1 Feb 2009	REPEAT PLANAR AND SINGLE PHOTON EMISSION TOMOGRAPHY IMAGING, OR REPEAT PLANAR IMAGING OR SINGLE PHOTON EMISSION TOMOGRAPHY IMAGING on an occasion subsequent to the performance of any one of items 61364, 61426, 61429, 61430, 61442, 61450, 61453, 61469, <u>61484 or 61485</u> where there is no additional administration of radiopharmaceutical and where the previous radionuclide scan was abnormal or equivocal. (R) <b>Fee:</b> \$129.00 <b>Benefit:</b> 75% = \$96.75 85% = \$109.65		
<b>61484</b> Amend 1 Feb 2009	ADRENAL STUDY <del>, with imaging on 2 or more separate occasions</del> (R) Fee: \$880.85 Benefit: 75% = \$660.65 85% = \$812.75		
<b>61485</b> Amend 1 Feb 2009	ADRENAL STUDY, with <del>imaging on 2 or more occasions and renal localisation and</del> single photon emission tomography (R) <b>Fee:</b> \$999.20 <b>Benefit:</b> 75% = \$749.40 85% = \$931.10		
<b>61541</b> Amend 1 Dec 2008	Whole body FDG PET study, performed in a symptomatic patient for the evaluation of a residual structural lesion, after definitive therapy for colorectal cancer, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy Fee: \$953.00 Benefit: 75% = \$714.75 85% = \$884.90		
<b>61544</b> Amend 1 Dec 2008	Whole body FDG PET study, performed in a symptomatic patient for the evaluation of a residual structural lesion after definitive therapy for colorectal cancer, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy with catheterisation of the bladder <b>Fee:</b> \$975.00 <b>Benefit:</b> 75% = \$731.25 85% = \$906.90		
<b>61553</b> Amend 1 Dec 2008	Whole body FDG PET study, performed for the evaluation of apparently limited metastatic disease from malignant melanoma, where surgical resection is planned following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy Fee: \$999.00 Benefit: 75% = \$749.25 85% = \$930.90		

GROUP I4 - NUCLEAR MEDICINE IMAGING		
<b>61556</b> Amend 1 Dec 2008	Whole body FDG PET study, performed for the evaluation of apparently limited metastatic disease from malignant melanoma, where surgical resection is planned, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy, with catheterisation of the bladder <b>Fee:</b> \$1,021.00 <b>Benefit:</b> 75% = \$765.75 85% = \$952.90	
<b>61565</b> Amend 1 Dec 2008	Whole body FDG PET study, performed for the evaluation of epithelial ovarian carcinoma with suspected tumour recurrence following initial therapy, based on equivocal anatomical imaging findings or an elevation of CA-125 following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. Fee: \$953.00 <b>Benefit:</b> 75% = \$714.75 85% = \$884.90	
<b>61568</b> Amend 1 Dec 2008	Whole body FDG PET study, performed for the evaluation of epithelial ovarian carcinoma with suspected tumour recurrence following initial therapy, based on equivocal anatomical imaging findings or an elevation of CA-125, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy with curative intent, with catheterisation of the bladder <b>Fee:</b> \$975.00 <b>Benefit:</b> 75% = \$731.25 85% = \$906.90	

Г

	SUBGROUP 19 - SCAN OF BODY - FOR SPECIFIED CONDITIONS
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where: (a) a dedicated breast coil is used; and (b) the request for scan identifies that the woman is less than 50 years of age; and (c) the request for scan identifies either: (i) that the patient is at high risk of developing breast cancer due to 1 of the following: (A) 3 or more first or second degree relatives on the same side of the family diagnosed with breast or ovarian cancer; (B) 2 or more first or second degree relatives on the same side of the family diagnosed with breast cancer ; - bilateral breast cancer; - onset of breast cancer before the age of 40 years; - onset of ovarian cancer in one relative; - breast and ovarian cancer in one relative; - breast and ovarian cancer in one relative; (C)1 first or second degree relative diagnosed with breast cancer at age 45 years or younger, plus another first or second degree relative or younger; or
	(ii) that genetic testing has identified the presence of a high risk breast cancer gene mutation.
	Scan of both breasts for:
63464	- detection of cancer (R)
New 1 Feb 2009	NOTE: Benefits are payable on one occasion only in any 12 month period (Anaes.) Fee: \$690.00 Benefit: 75% = \$517.50 85% = \$621.90
	MAGNETIC RESONANCE IMAGING performed under the professional supervision of an eligible provider at an eligible location where the patient is referred by a specialist or by a consultant physician and where: (a) a dedicated breast coil is used; and (b) the woman has had an abnormality detected as a result of a service described in item 63464 performed in the previous 12 months
	Scan of both breasts for:
	- detection of cancer (R)
	NOTE 1: Benefits are payable on one occasion only in any 12 month period
63467	NOTE 2: This item is intended for follow-up imaging of abnormalities diagnosed on a scan described by item 63464
New 1 Feb 2009	(Anaes.) Fee: \$690.00 Benefit: 75% = \$517.50 85% = \$621.90

1

## Category 8 – Miscellaneous Services

Γ

G	GROUP M1 - MANAGEMENT OF BULK-BILLED SERVICES
	A medical service to which item 1, 97, 601, <u>603, 696,</u> 697, 5003, 5007, 5010, 5023, 5026, 5028, 5043, 5046, 5049, 5063, 5064, 5067, 5220, 5223, 5227, 5228, 5240, 5243, 5247, 5248, 5260, 5263, 5265 or 5267 applies if:
	<ul> <li>(a) the service is an unreferred service; and</li> <li>(b) the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and</li> </ul>
	<ul> <li>(c) the person is not an admitted patient of a hospital; and</li> <li>(d) the service is not provided in consulting rooms; and</li> <li>(e) the service is provided in one of the following eligible areas:</li> </ul>
	<ul> <li>(i) a regional, rural or remote area; or</li> <li>(ii) Tasmania; or</li> <li>(iii) A geographical area included in any of the following SSD spatial units:</li> </ul>
	<ul> <li>(A) Beaudesert Shire Part A</li> <li>(B) Belconnen</li> <li>(C) Darwin City</li> </ul>
	<ul> <li>(D) Eastern Outer Melbourne</li> <li>(E) East Metropolitan, Perth</li> <li>(F) Frankston City</li> <li>(C) Confirmed Wayners</li> </ul>
	<ul> <li>(G) Gosford-Wyong</li> <li>(H) Greater Geelong City Part A</li> <li>(I) Gungahlin-Hall</li> <li>(I) Inswich City (part in RSD)</li> </ul>
	<ul> <li>(J) Ipswich City (part in BSD)</li> <li>(K) Litchfield Shire</li> <li>(L) Melton-Wyndham</li> <li>(M) Mornington Peninsula Shire</li> </ul>
	<ul> <li>(N) Newcastle</li> <li>(O) North Canberra</li> <li>(P) Palmerston-East Arm</li> </ul>
	Q) Pine Rivers Shire (R) Queanbeyan
	<ul> <li>(S) South Canberra</li> <li>(T) South Eastern Outer Melbourne</li> <li>(U) Southern Adelaide</li> <li>(V) South West Metropolitan, Perth</li> </ul>
	<ul> <li>(W) South West Metropolitall, Petri</li> <li>(W) Thuringowa City Part A</li> <li>(X) Townsville City Part A</li> <li>(Y) Tuggeranong</li> </ul>
	(Z) Weston Creek-Stromlo (ZA) Woden Valley (ZB) Yarra Ranges Shire Part A; or
	<ul> <li>(iv) the geographical area included in the SLA spatial unit of Palm Island (AC)</li> <li>(f) the service is provided by, or on behalf of, a medical practitioner whose practice location is not in an eligible area; and</li> </ul>
10992	(g) the service is bulk billed in respect of the fees for:
Amend	<ul><li>(i) this item; and</li><li>(ii) the other item in this table applying to the service.</li></ul>
1 Jan 2009	(See para M1.1 of explanatory notes to this Category)
2009	<b>Fee:</b> \$9.80 <b>Benefit:</b> 85% = \$8.35